The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy

Kano, Kazuki; Aoyama, Toru; Maezawa, Yukio; Nakajima, Tetsushi; Ikeda, Kousuke; Yamada, Takanobu; Sato, Tsutomu; Oshima, Takashi; Rino, Yasushi; Masuda, Munetaka; Ogata, Takashi; Cho, Haruhiko; Yoshikawa, Takaki

doi:10.1007/s10147-017-1128-8

Cited by 19 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peritoneal recurrence occurred in 62% of enrolled patients[ 18 ]. Similar results were confirmed by other groups from the East[ 19 - 21 ]. Kano et al [ 19 ] presented a retrospective study with a median follow-up of almost 10 years.…”

Section: Upfront Surgery For Cy1 Gc Patientssupporting

confidence: 92%

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Baušys¹,

Gricius²,

Aniukstyte³

et al. 2021

WJCC

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies worldwide and surgery remains the only potentially curative treatment option for it. Although a significant proportion of GC patients are found with distant metastases already at the initial diagnosis. Peritoneal dissemination is the most common site of metastases. Positive peritoneal cytology (Cy1) is associated with poor long-term outcomes; thus, these patients are considered as stage IV even if macroscopic carcinomatosis is absent. Currently, there is no clear evidence for the most optimal treatment for this distinct subpopulation of the stage IV cohort. Available strategies vary from palliative chemotherapy to upfront gastrectomy. This comprehensive review summarized current evidence of different treatment strategies for Cy1 GC including roles of surgery, systemic and intraperitoneal chemotherapy.

show abstract

Section: Upfront Surgery For Cy1 Gc Patientssupporting

confidence: 92%

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Baušys¹,

Gricius²,

Aniukstyte³

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…cN3 (vs. cN0-2) was shown to be a significant independent indicator for an unfavorable OS by multivariable analyses among CY1P0 patients [10,15,16]. Furthermore, Kano et al [17] showed that pN3b (vs. pN0-3a) was associated with an extremely poor prognosis. Saito et al [18] indicated that the prognosis of CY1P0 patients without pathological lymph node metastasis was good, whereas that of those with pathological lymph node metastasis was extremely poor.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for cytology-positive gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Scientific-based data regarding the treatment of gastric cancer patients with positive exfoliative cytology are not enough, and there is a need for large-scale, prospective randomized control trials. The results of CCOG0301 study demonstrated that CY1 patients could benefit from S-1 as adjuvant chemotherapy after radical gastrectomy [132], and it was further reported that their mOS could reach up to 22.3 months [133]. Selected P0CY1 gastric cancer patients may benefit from systemic chemotherapy in combination with surgery.…”

Section: Comprehensive Treatment Of Gastric Cancermentioning

confidence: 99%

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Wang

Shen

et al. 2019

Cancer Communications

520

442

View full text Add to dashboard Cite

China is one of the countries with the highest incidence of gastric cancer. There are differences in epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selection between gastric cancer patients from the Eastern and Western countries. Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients. The Chinese Society of Clinical Oncology (CSCO) arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile, discuss, and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad. By referring to the opinions of industry experts, taking into account of regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted experts’ consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes. This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis, comprehensive treatment, and follow-up visits for gastric cancer.

show abstract

The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy

Cited by 19 publications

References 37 publications

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Prognostic factors for cytology-positive gastric cancer

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Contact Info

Product

Resources

About